Nine-month results of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular oedema: A retrospective analysis

Patricia E. Kook, Mathias Maier, Tibor Schuster, Nikolaus Feucht, Chris P. Lohmann

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Objective: To compare efficacy of intravitreal bevacizumab versus triamcinolone in the treatment of diffuse diabetic macular oedema (DME). Methods: This retrospective nonrandomized study includes 60 patients with diffuse DME treated with at least one intravitreal triamcinolone injection (ITA) or intravitreal bevacizumab injection (IBe). Regression analysis was performed for pretreatment, glycosylated haemoglobin level, visual acuity (VA) at baseline and central macular thickness (CMT) at baseline. Results: After 1-, 3-, 6- and 9-month follow-up, there was no significant change in either VA or CMT treatment in the ITA and IBe groups. There was no statistically significant difference between the two treatment groups. Changes in CMT and VA in the subgroups were not significant. Only predictive factor independent of HbA1c level and VA was CMT at baseline in both treatment groups. The thicker CMT at baseline, the higher was reduction in CMT. After 1 month, the IBe group had a significantly higher decrement than the ITA group. Conclusion: In our study collective, neither IBe nor ITA treatment was able to improve VA during follow-up, significantly. CMT was reduced in both treatment groups, however not significantly. Our data demonstrates that reduction in CMT with either IBe or ITA treatment was significantly influenced by degree of CMT at baseline.

Original languageEnglish
Pages (from-to)769-773
Number of pages5
JournalActa Ophthalmologica
Volume89
Issue number8
DOIs
StatePublished - Dec 2011

Keywords

  • bevacizumab
  • diabetic macular oedema
  • intravitreal injection
  • triamcinolone

Fingerprint

Dive into the research topics of 'Nine-month results of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular oedema: A retrospective analysis'. Together they form a unique fingerprint.

Cite this